Helixmith Co., Ltd.

This early-stage study tested a new medicine called VM202 in 12 people with critical limb ischemia, a severe form of leg artery disease that causes pain and sores. The goal was to see if the injections are safe and tolerable. Participants had not gotten better with standard treat…

This early-phase trial tested whether an experimental drug called Engensis (VM202) is safe when injected into the weakened leg muscles of people with Charcot-Marie-Tooth disease type 1A (CMT1A). Twelve adults with mild to moderate CMT1A received multiple injections over 270 days.…

This early-stage study tested whether a gene therapy called VM202 is safe to inject directly into heart muscle areas that couldn't be fully repaired during bypass surgery. Nine adults with ischemic heart disease took part. The main goal was to check for side effects over six mont…

This study looked at the long-term safety of a drug called Engensis in 8 people with ALS who had already received the drug in an earlier trial. Researchers monitored side effects over 6 months. The goal was to see if repeated injections are safe, not to test if the drug works.

This study tested the safety of an experimental drug called engensis in 18 people with amyotrophic lateral sclerosis (ALS), a disease that weakens muscles over time. Participants received either engensis or a placebo injection into their muscles. The main goal was to check for si…

This study tested a gene therapy called VM202 (Engensis) in 52 people with critical limb ischemia, a severe blockage of leg arteries causing pain and risk of amputation. Participants received injections into the calf muscle to see if it safely improves blood flow and reduces pain…

This study looked at the long-term safety of a drug called Engensis (VM202) for people with painful diabetic peripheral neuropathy. It included 101 adults who had already received Engensis or a placebo in an earlier study. Researchers tracked side effects over 6 months and checke…

This study tested an experimental gene therapy called VM202 (Engensis) to see if it safely reduces pain in people with diabetic peripheral neuropathy. About 500 adults with type 1 or type 2 diabetes received either VM202 or a placebo injection into both legs. The main goal was to…

This study tested an experimental drug called Engensis to see if it could reduce pain in people with diabetic peripheral neuropathy, a common complication of diabetes causing nerve pain in the feet and legs. The trial involved 162 adults with type 1 or 2 diabetes who received eit…

This early-phase study tested an experimental gene therapy called Engensis (VM202) in 12 adults with painful diabetic peripheral neuropathy. Participants received injections into their leg muscles at different doses to check safety and whether it could reduce pain. The goal was t…

This study tested a gene therapy called Engensis (VM202) to see if it safely reduces pain in people with diabetic nerve damage. 104 adults with type 1 or 2 diabetes and leg pain for at least 6 months received either the treatment or a placebo. The main goal was to measure changes…

This study looked at whether a medicine called Engensis can safely reduce pain from diabetic nerve damage in the feet and legs over 6 extra months. 106 adults who had already been in a related study took part. The goal was to see if the pain relief lasts and if the treatment is s…

This early-stage study tested whether a drug called VM202 is safe to inject into muscles of people with amyotrophic lateral sclerosis (ALS). 18 adults with early ALS received the injections and were monitored for 9 months. The main goal was to check for side effects, not to cure …